Efficacy of treatment of extensive drug resistant tuberculosis in patients with different genotypes in the biotransformation enzyme genes of CYP2B6 and NAT2
https://doi.org/10.21292/2075-1230-2020-98-6-40-46
Abstract
The objective of the study: to evaluate the efficacy of treatment of extensive drug resistant tuberculosis (XDR-TB) in patients with different genotypes in the biotransformation system NAT2 (rs1041983, rs1799930, rs1799931, rs1801280) and CYP2B6 genes (rs3745274).
Subjects and methods. The study involved patients undergoing in-patient treatment at Republican Clinical TB Dispensary in Ufa from 2016 to 2018. XDR TB group included 210 people; the control group included 343 healthy donors. Molecular genetic analysis was performed on DNA samples isolated from peripheral blood leukocytes. Genotyping of polymorphic loci was carried out by kompetitive allele specific PCR (KASP).
Results. It was revealed that polymorphic loci rs1799931 of NAT2 gene and rs3745274 of CYP2B6 gene were associated with the risk of developing XDR TB. Regression analysis detected combinations of the predictor genotypes of rs1799931*G/A × rs3745274*G/T and rs1799931*G/G × rs37455274*(G/G+T/T), that significantly reduce efficacy of XDR TB treatment.
Supporting agencies: This study was financially supported by the Russian Foundation for Fundamental Research as part of Research Project No. 17-44-020697.
About the Authors
M. M. Yunusbаevа
Biochemistry and Genetics Institute of Ufa Federal Research Center of the Russian Academy of Sciences
Russian Federation
Russian Federation
Milyausha M. Yunusbaeva, Candidate of Biological Sciences, Senior Researcher of Molecular Human Genetics Laboratory.
71, Octyabrya Ave., Ufa, 450054.
L. Ya. Borodinа
Republican Clinical TB Dispensary
Russian Federation
Russian Federation
Liliya Ya. Borodina, Phthisiologist of Superior Merit, Head of MDR Tuberculosis Department.
4, Agisha St., Ufa, 450080.
Phone: +7 (347) 228-45-14.
F. S. Bilаlov
Bashkiriya State Medical University
Russian Federation
Russian Federation
Fanil S. Bilalov, Doctor of Medical Sciences, Associate Professor of Laboratory Diagnostics Department.
3, Lenina St., Ufa, 450008.
R. A. Shаripov
Republican Clinical TB Dispensary
Russian Federation
Russian Federation
Raul A. Sharipov, Head Physician.
4, Agisha St., Ufa, 450080.
Phone: +7 (347) 228-45-14.
T. R. Nаsibullin
Biochemistry and Genetics Institute of Ufa Federal Research Center of the Russian Academy of Sciences
Russian Federation
Russian Federation
Timur R. Nasibullin, Candidate of Biological Sciences, Senior Researcher.
71, Octyabrya Ave., Ufa, 450054.
B. B. Yunusbаev
University of Tartu
Estonia
Estonia
Bayazit B. Yunusbaev, Candidate of Biological Sciences, Leading Researcher of Evolution Genomics Laboratory.
18 Ülikooli, Tartu, Estonia, 50090
References
1. Mozhokina G.N., Kazakov А.V., Elistratova N.А., Popov S.А. Biotransformation enzymes for xenobiotics and personalization of treatment regimens for tuberculosis patients. Tuberculosis and Lung Diseases, 2016, vol. 94, no. 4, pp. 6-12. (In Russ.)
2. Edict no. 186 by the Russian Ministry of Health dated April 24, 2018, On Approval of the Concept of Predictive, Preventive and Personalized medicine.(In Russ.)
3. Jakulin A., Bratko I. Testing the significance of attribute interactions. Proceedings of the Twenty-first International Conference on Machine Learning (ICML-2004). Eds. R. Greiner, D. Schuurmans. Banff, Canada, 2004, pp. 409-416.
4. Mathew C.G.P. The Isolation of High Molecular Weight Eukaryotic DNA. In: Walker J.M. (eds) Nucleic Acids. Methods in Molecular Biology. 1984, vol. 2, Humana Press. pp. 154-344.
5. Richardson M., Kirkham J., Dwan K., Sloan D.J., Davies G., Jorgensen A.L. NAT2 variants and toxicity related to anti-tuberculosis agents: a systematic review and meta-analysis. Int. J. Tuberc. Lung Dis., 2019, vol. 23, no. 3, pp. 293-305.
6. Richardson M., Kirkham J., Dwan K., Sloan D., Davies G., Jorgensen A. CYP genetic variants and toxicity related to anti-tubercular agents: a systematic review and meta-analysis. Syst. Rev., 2018, vol. 7, no. 1, pp. 204.
7. Wattanapokayakit S., Mushiroda T., Yanai H., Wichukchinda N., Chuchottawon C., Nedsuwan S., Rojanawiwat A., Denjanta S., Kantima T., Wongyai J., Suwankesawong W., Rungapiromnan W., Kidkeukarun R., Bamrungram W., Chaiwong A., Suvichapanich S., Mahasirimongkol S., Tokunaga K. NAT2 slow acetylator associated with anti-tuberculosis drug-induced liver injury in Thai patients. Int. J. Tuberc. Lung Dis., 2016, vol. 20, no. 10, pp. 1364-1369.
8. Werely C.J., Donald P.R., van Helden P.D. NAT2 polymorphisms and their influence on the pharmacology and toxicity of isoniazid in TB patients. Per. Med., 2007, no. 4, pp. 123-131.
9. Zanger U.M., Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther., 2013, no. 138, pp. 103-141.
10. Zhou S.F., Liu J.P., Chowbay B. Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug. Metab. Rev., 2009, vol. 41, no. 2, pp. 289-295.
Review
For citations:
Yunusbаevа M.M., Borodinа L.Ya., Bilаlov F.S., Shаripov R.A., Nаsibullin T.R., Yunusbаev B.B. Efficacy of treatment of extensive drug resistant tuberculosis in patients with different genotypes in the biotransformation enzyme genes of CYP2B6 and NAT2. Tuberculosis and Lung Diseases. 2020;98(6):40-46. (In Russ.) https://doi.org/10.21292/2075-1230-2020-98-6-40-46
Views:
893
Email this article 